{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T17:22:47Z","timestamp":1743528167806},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00393-024-01484-0","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T16:02:16Z","timestamp":1706544136000},"page":"112-121","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Polymyalgia rheumatica\u00a0\u2013 eine Herausforderung in der Altersmedizin","Polymyalgia rheumatica\u2014A\u00a0challenge in geriatrics"],"prefix":"10.1007","volume":"83","author":[{"given":"W.","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Winterhalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Krupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"1484_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-018-0476-8","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit\u00a0F, Dejaco\u00a0C, Matteson\u00a0EL, Dasgupta\u00a0B (2016) Polymyalgia rheumatica and giant cell Arteritis: a systematic review. JAMA. https:\/\/doi.org\/10.1007\/s00393-018-0476-8","journal-title":"JAMA"},{"key":"1484_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40266-019-00705-S","volume":"36","author":"D Camellino","year":"2019","unstructured":"Camellino\u00a0D, Giusti\u00a0A, Girasole\u00a0G et\u00a0al (2019) Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging 36:1015\u20131026. https:\/\/doi.org\/10.1007\/s40266-019-00705-S","journal-title":"Drugs Aging"},{"key":"1484_CR3","first-page":"1","volume-title":"Clinical manifestations and diagnosis of polymyalgia rheumatica. Version 25","author":"C Salvarani","year":"2022","unstructured":"Salvarani\u00a0C, Muratore\u00a0F (2022) Clinical manifestations and diagnosis of polymyalgia rheumatica. Version 25. Wolters Kluwer, S\u00a01\u201324"},{"key":"1484_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3238\/arztebl.m2022.0218","volume":"119","author":"MG Colombo","year":"2022","unstructured":"Colombo\u00a0MG, Wetzel\u00a0AJ, Haumann\u00a0H et al (2022) Polymyalgia rheumatica. Geschlechtsspezifische Epidemiologie, diagnostisch-therapeutisches Vorgehen und \u00e4rztliche Versorgung. Dtsch \u00c4rztebl 119:411\u2013417. https:\/\/doi.org\/10.3238\/arztebl.m2022.0218","journal-title":"Dtsch \u00c4rztebl"},{"key":"1484_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/acr.23060","volume":"69","author":"S Raheel","year":"2017","unstructured":"Raheel\u00a0S, Shbeeb\u00a0I, Crowson\u00a0CS, Matteson\u00a0EL (2017) Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res 69:1282\u20131285. https:\/\/doi.org\/10.1002\/acr.23060","journal-title":"Arthritis Care Res"},{"key":"1484_CR6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.10016\/j.semarthrit.2020.07.005","volume":"50","author":"A Sharma","year":"2020","unstructured":"Sharma\u00a0A, Mohammad\u00a0AJ, Turesson\u00a0C (2020) Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 50:1040\u20131048. https:\/\/doi.org\/10.10016\/j.semarthrit.2020.07.005","journal-title":"Semin Arthritis Rheum"},{"key":"1484_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta\u00a0B, Cimmino\u00a0MA, Kremers\u00a0HM et\u00a0al (2012) Provisional classification criteria for polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484\u2013492. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200329","journal-title":"Ann Rheum Dis"},{"key":"1484_CR8","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X699667","author":"T Helliwell","year":"2018","unstructured":"Helliwell\u00a0T, Muller\u00a0S, Hider\u00a0SL et al (2018) Challenges of diagnosing and managing polymyalgia rheumatica: a\u00a0multi-methods study in UK general practice. Br J Gen Pract. https:\/\/doi.org\/10.3399\/bjgp18X699667","journal-title":"Br J Gen Pract"},{"key":"1484_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s10067-017-3730-6","volume":"37","author":"A Cawley","year":"2018","unstructured":"Cawley\u00a0A, Prior\u00a0JA, Muller\u00a0S et\u00a0al (2018) Association between characteristics of pain and stiffness and the functional status of patients with incident polymyalgia rheumatica from primary care. Clin Rheumatol 37:1639\u20131644. https:\/\/doi.org\/10.1007\/s10067-017-3730-6","journal-title":"Clin Rheumatol"},{"key":"1484_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00296-020-04611-7","volume":"40","author":"B Pittam","year":"2020","unstructured":"Pittam\u00a0B, Gupta\u00a0S, Ahmed\u00a0AE et al (2020) The prevalence and impact of depression in primary systemic vasculitis: a\u00a0systematic review and meta-analysis. Rheumatol Int 40:1215\u20131221. https:\/\/doi.org\/10.1007\/s00296-020-04611-7","journal-title":"Rheumatol Int"},{"key":"1484_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10067-017-3691-9","volume":"37","author":"A Vivekanantham","year":"2018","unstructured":"Vivekanantham\u00a0A, Blagojevic-Bucknall\u00a0M, Clarkson\u00a0K et al (2018) How common is depression in patients with polymyalgia rheumatica? Clin Rheumatol 37:1633\u20131638. https:\/\/doi.org\/10.1007\/s10067-017-3691-9","journal-title":"Clin Rheumatol"},{"key":"1484_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","volume":"57","author":"V Devauchelle-Pensec","year":"2018","unstructured":"Devauchelle-Pensec\u00a0V, Saraux\u00a0L, Berhelot\u00a0JM et al (2018) Assessing polymyalgia rheumatica activity when C\u2011reactive protein is unavailable or uninterpretable. Rheumatology 57:666\u2013670. https:\/\/doi.org\/10.1093\/rheumatology\/kex477","journal-title":"Rheumatology"},{"key":"1484_CR13","doi-asserted-by":"crossref","unstructured":"Berlit P, Kr\u00e4mer M (2018) S1-Leitlinie Zerebrale Vaskulitis und zerebrale Beteiligung bei systemischen Vaskulitiden und rheumatischen Grunderkrankungen. DGN. https:\/\/register.awmf.org\/assets\/guidelines\/030-085l_S1_Zerebrale_Vaskulitis_2018-5.pdf. Zugegriffen: 24. Febr. 2023","DOI":"10.1007\/s42451-018-0001-y"},{"issue":"Suppl","key":"1484_CR14","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1007\/s00393-020-00893-1","volume":"79","author":"JH Schirmer","year":"2020","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, Balzer\u00a0K et al (2020) 2Sk-Leitlinie: Management der Gro\u00dfgef\u00e4\u00dfvaskulitiden. Z\u00a0Rheumatol 79(Suppl):S67\u2013S95. https:\/\/doi.org\/10.1007\/s00393-020-00893-1","journal-title":"Z Rheumatol"},{"key":"1484_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13075-018-1757-y","volume":"20","author":"R Partington","year":"2018","unstructured":"Partington\u00a0R, Hellwell\u00a0T, Muller\u00a0S et\u00a0al (2018) Comorbidities in polymyalgia rheumatica: a\u00a0systematic review. Arthritis Res Ther 20:258\u2013261. https:\/\/doi.org\/10.1186\/s13075-018-1757-y","journal-title":"Arthritis Res Ther"},{"key":"1484_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/art.41774","author":"M Maz","year":"2021","unstructured":"Maz\u00a0M, Chung\u00a0SA, Abril\u00a0A (2021) American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41774","journal-title":"Arthritis Rheumatol"},{"key":"1484_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00296-014-3034-y","volume":"34","author":"E Dalkihic","year":"2014","unstructured":"Dalkihic\u00a0E, Tufan\u00a0AN, Hafizoglu\u00a0E et\u00a0al (2014) The process from symptom onset to rheumatology clinic in polymyalgia rheumatica. Rheumatol Int 34:1589\u20131592. https:\/\/doi.org\/10.1007\/s00296-014-3034-y","journal-title":"Rheumatol Int"},{"key":"1484_CR18","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco\u00a0C, Singh\u00a0YP, Perel\u00a0P et\u00a0al (2015) Recommendations for the management of polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74:1799\u20131807. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207492","journal-title":"Ann Rheum Dis"},{"key":"1484_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00976-0","author":"C Perricone","year":"2022","unstructured":"Perricone\u00a0C, Cafaro\u00a0G, Fiumicelli\u00a0E et al (2022) Predictors of complete 24-month remission and fare in patients with polymyalgia rheumatica. Clin Experiment Med. https:\/\/doi.org\/10.1007\/s10238-022-00976-0","journal-title":"Clin Experiment Med"},{"key":"1484_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s0393-021-01145-6","volume":"81","author":"C Fiehn","year":"2022","unstructured":"Fiehn\u00a0C, Bauhammer\u00a0J (2022) Medikamenteninduzierte Osteopathien in der Rheumatologie. Z\u00a0Rheumatol 81:189\u2013197. https:\/\/doi.org\/10.1007\/s0393-021-01145-6","journal-title":"Z Rheumatol"},{"key":"1484_CR21","doi-asserted-by":"publisher","first-page":"E680","DOI":"10.1503\/cmaj.190178","volume":"24","author":"J Wu","year":"2019","unstructured":"Wu\u00a0J, Keeley\u00a0A, Mallen\u00a0C et\u00a0al (2019) Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a\u00a0cohort study in England. CMAJ 24:E680\u2013E688. https:\/\/doi.org\/10.1503\/cmaj.190178","journal-title":"CMAJ"},{"key":"1484_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/acr.23320","volume":"70","author":"I Shbeeb","year":"2018","unstructured":"Shbeeb\u00a0I, Challah\u00a0D, Raheel\u00a0S et al (2018) Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res 70:643. https:\/\/doi.org\/10.1002\/acr.23320","journal-title":"Arthritis Care Res"},{"key":"1484_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris\u00a0A, Piga\u00a0M, Chessa\u00a0E et al (2022) Long-term glucocorticoid treatment and high relapse remain unresolved issues in the real-life management of polymyalgia rheumatica: a\u00a0systematic literature review and meta-analysis. Clin Rheumatol 41:19\u201331. https:\/\/doi.org\/10.1007\/s10067-021-05819-z","journal-title":"Clin Rheumatol"},{"key":"1484_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00296-020-04783-32","volume":"41","author":"DE Marsmann","year":"2021","unstructured":"Marsmann\u00a0DE, Bolhuis\u00a0TH, Broeder\u00a0N, Maas\u00a0A (2021) Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoid tapering: a\u00a0retrospective study. Rheumatol Int 41:611\u2013616. https:\/\/doi.org\/10.1007\/s00296-020-04783-32","journal-title":"Rheumatol Int"},{"key":"1484_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13063-022-06263-3","volume":"23","author":"DE Marsmann","year":"2022","unstructured":"Marsmann\u00a0DE, Bolhuis\u00a0TH, Broeder\u00a0N, Maas\u00a0A (2022) PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Elderly disease phase (PMR MODE): study protocol for a\u00a0multicenter double-blind placebo controlled trial. BMC 23:318. https:\/\/doi.org\/10.1186\/s13063-022-06263-3","journal-title":"BMC"},{"key":"1484_CR26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/sjama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec\u00a0V, Carvajal-Alegria\u00a0G, Dernis\u00a0E et al (2022) Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA 328:1053\u20131062. https:\/\/doi.org\/10.1007\/sjama.2022.15459","journal-title":"JAMA"},{"key":"1484_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.806","author":"N Venhoff","year":"2022","unstructured":"Venhoff\u00a0N, Schmitt\u00a0WA, Bergner\u00a0R et al (2022) Secukinumab in giant cell arteritis: the randomised, parallel-group, double-blind, placebo-controlled, multicentre phase 2 titain trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.806","journal-title":"Ann Rheum Dis"},{"key":"1484_CR28","unstructured":"Pazan F, Wei\u00df C, Wehling M (2021) FORTA-Liste 2021 mit Kommentaren und Hinweisen. https:\/\/www.umm.uni-heidelberg.de\/experimentelle-pharmakologie\/research\/gruppe-wehling. Zugegriffen: 15. Jan. 2023"},{"key":"1484_CR29","unstructured":"Krupp S (2022) S1-Leitlinie \u201eGeriatrisches Assessment der Stufe 2, Living Guideline. https:\/\/register.awmf.org\/assets\/guidelines\/084-002LGl_S1_Geriatrisches-Assessment-Stufe_2_2022-10.pdf. Zugegriffen: 24. Febr. 2023"},{"key":"1484_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00391-022-02041-7","author":"S Krupp","year":"2022","unstructured":"Krupp\u00a0S, Sch\u00f6ne\u00a0F, Balck\u00a0F et al (2022) Selbstbeurteilung von Alltagsaktivit\u00e4ten mittels Duru\u00f6z-Hand-Index \u2013 Validierung der deutschen \u00dcbersetzung. Z\u00a0Gerontol Geriatr. https:\/\/doi.org\/10.1007\/s00391-022-02041-7","journal-title":"Z Gerontol Geriatr"},{"key":"1484_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00391-014-0854-z","volume":"48","author":"S Krupp","year":"2015","unstructured":"Krupp\u00a0S, Kasper\u00a0J, Balck\u00a0F et al (2015) \u201eTimed up and go\u201c f\u00fcr die Finger in Form des 20-Cents-Tests. Psychometrische G\u00fctekriterien eines einfachen Feinmotorik-Performance-Tests. Z\u00a0Gerontol Geriat 48:121\u2013127. https:\/\/doi.org\/10.1007\/s00391-014-0854-z","journal-title":"Z Gerontol Geriat"},{"key":"1484_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00391-022-02029-3","volume":"55","author":"S Krupp","year":"2022","unstructured":"Krupp\u00a0S, Petersen\u00a0T, Balck\u00a0F et al (2022) Die Hand positionieren, um zu agieren \u2013 Validierung des 8\u2011Punkte-Greifraum-Tests. Z\u00a0Gerontol Geriat 55:93\u201398. https:\/\/doi.org\/10.1007\/s00391-022-02029-3","journal-title":"Z Gerontol Geriat"},{"key":"1484_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102868","author":"M Vieira","year":"2022","unstructured":"Vieira\u00a0M, Comarmond\u00a0G, Labreuche\u00a0J et al (2022) COVID-19 outcomes in giant arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study. J\u00a0Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2022.102868","journal-title":"J Autoimmun"},{"key":"1484_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5114\/rheum.2022.115665","volume":"60","author":"C Manzo","year":"2022","unstructured":"Manzo\u00a0C, Castagna\u00a0A, Isetta\u00a0M (2022) Polymyalgia rheumatica and polymyalgia-like syndromes as adverse following COVD-19 vaccines: working notes from an narrative review of publishes literature. Rheumatologia 60:142\u2013147. https:\/\/doi.org\/10.5114\/rheum.2022.115665","journal-title":"Rheumatologia"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01484-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:06:49Z","timestamp":1709132809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01484-0"}},"subtitle":["Diagnostik und Therapie interdisziplin\u00e4r dargestellt","Interdisciplinary presentation of diagnostics and treatment"],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01484-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"29 January 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>W.\u00a0Hofmann<\/b>: A.\u00a0Finanzielle Interessen: bis 2022 MA Institut f\u00fcr Allgemeinmedizin Uni L\u00fcbeck.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: bis 2022 Hrsg. <i>ZGG<\/i>, aktuell Steuergr. AWMF-LL 084-003. <b>I.\u00a0K\u00f6tter<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: AbbVie, AMGEN, BMS, GSK, Janssen, Lilly, MEDAC, Novartis, Pfizer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktorin, Klinik f\u00fcr Rheumatologie und Immunologie, Klinikum Bad Bramstedt, Oskar-Alexander-Stra\u00dfe\u00a026, 24576 Bad Bramstedt; Leiterin der Sektion Rheumatologie und entz\u00fcndliche Systemerkrankungen, Universit\u00e4tsklinikum Hamburg-Eppendorf, Martinistr.\u00a052, 20246 Hamburg | Mitgliedschaften: Vorstand der DGRh, Beirat International Society for Behcet\u2019s Disease; Vorstand des Verbandes Rheumatologischer Akut-Kliniken VRA; DGIM; DGFI; ACR; DGRh; VRA. <b>S.\u00a0Winterhalter<\/b>: A.\u00a0Finanzielle Interessen: Allergan: Reisekostenerstattung, XEN Schulungstreffen Salzburg 2018. AbbVie: Vortrag XEN 3\/2023 AAD D\u00fcsseldorf.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte Augen\u00e4rztin, Ober\u00e4rztin, Klinik f\u00fcr Augenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Campus Virchow Klinikum, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin und Berlin Institute of Health | Mitgliedschaften: DOG, DUAG, BBAG. <b>S.\u00a0Krupp<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Kostenerstattung vom BDI f\u00fcr Referat zum geriatrischen Assessment.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: wiss. Leitung der Forschungsgruppe Geriatrie L\u00fcbeck; Ober\u00e4rztin des Krankenhaus Rotes Kreuz L\u00fcbeck, Geriatriezentrum.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: wiss. Leitung der Forschungsgruppe Geriatrie L\u00fcbeck; Ober\u00e4rztin des Krankenhaus Rotes Kreuz L\u00fcbeck, Geriatriezentrum. | Mitgliedschaften: DGG, DGGG, Zentrum f\u00fcr Bev\u00f6lkerungsmedizin und Versorgungsforschung der Universit\u00e4t zu L\u00fcbeck, AG Bewegungsbezogene Versorgungsforschung der DNVF, AG Pr\u00e4vention der DGGG, Sprecherin der AG Assessment der DGG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}